lovastatin has been researched along with Dyslipidemias in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Sashidhara, KV; Singh, SP | 1 |
| Endo, A; Hattori, A; Hayashi, A; Ide, K; Ide, S; Inagaki, M; Ishikawa, T; Kitamoto, T; Kobayashi, J; Kobayashi, K; Koshizaka, M; Maezawa, Y; Minamizuka, T; Sakamoto, K; Shoji, M; Takemoto, M; Yamaga, M; Yokote, K | 1 |
| Banach, M; Catapano, AL; Cicero, AFG; Escobar, C; Foger, B; Katsiki, N; Latkovskis, G; Penson, PE; Rakowski, M; Reiner, Z; Sahebkar, A; Sikand, G | 1 |
| Androulakis, I; Angelopoulos, N; Argyrakopoulou, G; Boniakos, A; Livadas, S; Paparodis, RD | 1 |
| Di Pierro, F; Putignano, P; Villanova, N | 1 |
| Abdul Rahman, H; Ahmad, Z; C Thambiah, S; Chew, BH; Hasan, S; Meor Anuar Shuhaili, MFR; Samsudin, IN; Stanslas, J | 1 |
| Esposito, G; Izzo, R; Manzi, MV; Rozza, F; Santoro, M; Schiattarella, GG; Serino, F; Stabile, E; Trimarco, B; Trimarco, V | 1 |
| Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G | 1 |
| Chen, Y; Chen, YG; Guo, T; Jia, M; Li, P; Liang, WJ; Liu, LY; Ma, H; Peng, QS; Shan, MR; Sun, XY; Wang, F; Wang, SX; Wang, XQ; Yang, JJ; Yin, YL; Zhang, JN | 1 |
| Charland, SL; Malone, DC | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
| Davydova, N; Gotfrid, I; Kerimkulova, A; Lunegova, O; Mirrakhimov, A; Mirrakhimov, E; Moldokeeva, C; Noruzbaeva, A | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN | 1 |
| Melone, M; Palyha, O; Rashid, S; Strack, A; Wilsie, L | 1 |
| Bays, HE | 1 |
| Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S | 1 |
| Bays, HE; McGovern, ME | 1 |
| Davidson, M | 1 |
| Hegele, RA; Liu, DM; Miskie, BA; Tadiboyina, VT; Wang, J | 1 |
| Brown, BG; Brunzell, JD; Hokanson, JE; Motulsky, AG; Zambon, A | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Gupta, R; Hira, HS; Kumar, N; Mohan, B; Panwar, RB; Sharma, DR; Sharma, M; Sharma, SK; Singh, V | 1 |
5 review(s) available for lovastatin and Dyslipidemias
| Article | Year |
|---|---|
Lipid lowering agents of natural origin: An account of some promising chemotypes.
Topics: Animals; Biological Products; Dyslipidemias; Humans; Hypolipidemic Agents | 2017 |
Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel.
Topics: Anticholesteremic Agents; Biological Products; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Heart Disease Risk Factors; Humans; Lovastatin; Proprotein Convertase 9; Risk Factors; Risk Reduction Behavior | 2022 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
Topics: Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Lovastatin; Niacin | 2004 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
7 trial(s) available for lovastatin and Dyslipidemias
| Article | Year |
|---|---|
Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial.
Topics: Biological Products; Blood Pressure; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Humans; Hypercholesterolemia; Japan; Lovastatin | 2021 |
Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Humans; Hypercholesterolemia; Lovastatin; Olea; Vitis | 2023 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Dyslipidemias; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin; Insulin Resistance; Italy; Lipids; Lovastatin; Male; Middle Aged; Morus; Plant Extracts; Plant Leaves; Time Factors; Treatment Outcome; Vasodilation | 2015 |
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Topics: Adult; Antioxidants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Hirsutism; Humans; Hyperandrogenism; Inositol; Insulin Resistance; Lovastatin; Polycystic Ovary Syndrome; Thioctic Acid; Young Adult | 2015 |
Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease.
Topics: Adult; Aged; Coronary Artery Disease; Diet, Fat-Restricted; Dyslipidemias; Echocardiography; Electrocardiography, Ambulatory; Exercise; Exercise Test; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Stroke Volume; Ventricular Function, Left; Ventricular Remodeling | 2011 |
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Dyslipidemias; Genetic Predisposition to Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin; Pharmacogenetics; Treatment Outcome | 2006 |
Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
Topics: Apolipoprotein A-I; Apolipoproteins B; Asian People; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Humans; Hypolipidemic Agents; India; Lipoprotein(a); Lovastatin; Male; Middle Aged; Niacin; Time Factors; Triglycerides | 2006 |
11 other study(ies) available for lovastatin and Dyslipidemias
| Article | Year |
|---|---|
Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia.
Topics: Aged; Berberine; Biological Products; Diabetes Mellitus; Dietary Supplements; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Lipids; Lovastatin; Male; Middle Aged; Retrospective Studies; Silymarin | 2018 |
A pilot study on the association between
Topics: Adult; Dyslipidemias; Female; Humans; Incidence; Liver-Specific Organic Anion Transporter 1; Lovastatin; Malaysia; Male; Middle Aged; Muscular Diseases; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Risk Factors; Simvastatin | 2019 |
Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Aorta; Cardiovascular Diseases; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Dyslipidemias; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Lovastatin; MicroRNAs; Nuclear Proteins; Oxidative Stress; Proteasome Endopeptidase Complex; RNA Interference; Signal Transduction; Time Factors; Transfection; Up-Regulation; Vasodilation | 2017 |
[Effect of lovastatin on adhesive and aggregation function of platelets in patients with arterial hypertension and dislipidemia].
Topics: Blood Platelets; Cell Adhesion; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Peroxidation; Lipids; Lovastatin; Male; Middle Aged; Platelet Aggregation | 2010 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin | 2011 |
Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.
Topics: Dose-Response Relationship, Drug; Dyslipidemias; Hep G2 Cells; Hepatocytes; Humans; Immunoprecipitation; Lovastatin; Models, Biological; Obesity; Proprotein Convertases; Real-Time Polymerase Chain Reaction; Receptors, LDL; Resistin; RNA, Messenger; Subtilisin | 2012 |
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.
Topics: Adolescent; Amino Acid Sequence; Azetidines; Base Sequence; Child; Child, Preschool; Cholesterol Ester Storage Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Lipoproteins; Lovastatin; Male; Molecular Sequence Data; Sterol Esterase | 2005 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |